Skip to Content
  • Autism

    Thimerosal – A Chemical Point

    I haven’t posted on this issue recently (although I’m working on a column for TechCentral Station,) but Dr. Manhattan has been writing some good pieces on it (check the comments sections for more.) There’s one thing I’d like to add, as an organic chemist. A persistant statement that I see about thimerosal is that it’s… Read More
  • Autism

    Thimerosal – a Chemical Point

    I haven’t posted on this issue recently (although I’m working on a column for TechCentral Station,) but Dr. Manhattan has been writing some good pieces on it (check the comments sections for more.) There’s one thing I’d like to add, as an organic chemist. A persistant statement that I see about thimerosal is that it’s… Read More
  • Autism

    Clearance Sale

    While I’m on the subject, I’ll mention some details that will be familiar to my fellow medicinal chemists. The body has a lot of mechanisms to deal with foreign substances. We assume that all our drugs are going to be handled by them, one way or another, and we just try to keep the stuff… Read More
  • Cardiovascular Disease

    Trials of Trials

    As I mentioned yesterday, I think the kind of study that compared diuretics with other hypertension medicines was a very good thing. So why don’t we see more of these? There are several reasons. It’s worth thinking about the different levels of testing, and what questions they’re designed to answer. At the first level, you… Read More
  • "Me Too" Drugs

    Hypertension and Marketing

    There were plenty of stories in the press today about the ALLHAT study, which showed that diuretics are still the most effective way to treat hypertension in most people. Let me say right off that I really like this kind of study, and I think that there should be more of them (more on this… Read More
  • General Scientific News

    Looking Back, Looking Forward

    I’ve been Christmas shopping for my two kids (ages 4 and 2 1/2) and have seen plenty of things that they’ll be getting when they’re older. Like chemistry sets – although the ones they sell now (standard chemist’s complaint coming) are wimpy and underpowered. But there are ways of fixing that. When I was around… Read More
  • Who Discovers and Why

    Attitude

    Now that I’ve had a chance to look over the Wall Street Journal’s article on Bristol-Meyers Squibb, it occurs to me that I’ve seen this behavior many times. I don’t mean the financial voodoo (although I’ve seen that at second hand, just like anyone else who pays attention to the markets.) What I mean is… Read More
  • Why Everyone Loves Us

    A Rough Business

    The front page of today’s Wall St. Journal featured a long story on just exactly how Bristol-Meyers Squibb cooked their books to make sales and earnings appear better. They’re in the middle of restating a couple of years worth of financial results, so the article was timely. I haven’t been able to see all of… Read More
  • Life in the Drug Labs

    A Quick One While He’s Away

    This is one of those nights I warned about, when there’s not much time for blogifying. My book chapter is headed out via overnight delivery tomorrow, full of corrections. That’s not as bad as it sounds – they’re things like a missed patronymic initial on a Soviet-era reference’s co-author’s name. A few are larger… Read More
  • Patents and IP

    Don’t Wait – Patent Today!

    GlaxoSmithKline won an interesting patent fight in Canada the other day. This has been going for quite a while, as you’ll be able to tell when I mention that involves AZT. Canadian generic companies Aponex and Novopharm had been trying to show that Glaxo’s patent was invalid – and Glaxo had been trying to recover… Read More
...531532533...